Evidence map›Paper›PMID 34956553›Full record

ArticleJournal of healthcare engineering2021

A Clinical Study on the Effect of Different Ratios of Recombinant Human Bone Morphogenetic Protein-2 Compound to Autogenous Bone on Cervical Interbody Fusion Based on Smart Healthcare.

Xinzhu Zhang, Kun Zhao, Feng Yuan, Youlai Yu, Bin Deng

RetractedAbstract readRetracted Publication
In one paragraph

Article in Journal of healthcare engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Xinzhu ZhangDepartment of Spinal Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China.ORCID 0000-0002-8696-1309
Kun ZhaoClinical Laboratory, Xuzhou Maternal and Child Health Care Hospital, Xuzhou, Jiangsu 221000, China.ORCID 0000-0001-5346-1095
Feng YuanDepartment of Spinal Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China.ORCID 0000-0002-4005-4164
Youlai YuDepartment of Spinal Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China.ORCID 0000-0002-8879-8111
Bin DengDepartment of Spinal Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, China.ORCID 0000-0002-9371-6846

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With an increasing elderly population worldwide, the incidence of spine degenerative diseases with neck and shoulder pain as the main symptom is rising obviously, which has now become one of the important and difficult problems in sociomedical science. This study was to explore the effects of different ratios of recombinant human bone morphogenetic protein-2 (rhBMP-2) compound to the autogenous bone on cervical interbody fusion. 90 cervical degeneration patients with the need of surgical treatment admitted to our hospital from January 2019 to January 2020 were selected as the research objects and equally divided into group A, group B, and group C according to the order of admission, with 30 cases in each group and the ratios of rhBMP-2 compound to autogenous bone being 2 : 1, 1 : 1, and 1 : 2 respectively, and standard anterior cervical diskectomy and fusion (ACDF) treatment was performed to all patients to compare their surgery-related indexes, the Japanese Orthopaedic Association (JOA) score, the visual analog scale (VAS) score, the effect of cervical interbody fusion, and the postoperative complication rate (CR). Compared with group A and group C, group B achieved the significantly better surgery-related indexes (

Indexed as

Cervical VertebraeSpinal FusionAgedBone Morphogenetic Protein 2HumansRecombinant ProteinsTransforming Growth Factor betaTreatment OutcomeBone Morphogenetic Protein 2recombinant human bone morphogenetic protein-2Recombinant ProteinsTransforming Growth Factor beta

Identifiers

PMID34956553
PMCPMC8702310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.